Adagio Therapeutics

change direction new plan alter arrows move reprioritize

Biotech

Invivyd evolves yet again to keep pace with COVID-19

Invivyd, launched in the early days of the pandemic as Adagio to find treatments for COVID-19, is hoping the third monoclonal antibody is the charm.

Annalee Armstrong Mar 6, 2023 10:45am

Layoffs

Invivyd faces C-suite departures, commercial layoffs

Oct 14, 2022 10:29am

image of a few paragliders

Catalent shakes up leadership, taps new CEO—Chutes & Ladders

Jul 8, 2022 9:30am

CEO chair executive leadership

Adagio selects permanent CEO after founding leader's resignation

Jul 5, 2022 11:17am

Resist resistance fight against cancer arrows out tumor immunotherapy

Adagio still hopes to build omicron offense for COVID-19 therapy

May 13, 2022 10:31am

venture capital funding

Biotech's top 10 money raisers of 2021

Apr 18, 2022 3:00am